摘要
目的研究慢性心力衰竭（CHF）患者心力衰竭严重程度与其血浆脑钠肽（BNP）浓度的关系，探讨不同剂量雷米普利对CHF患者BNP的影响和较大剂量雷米普利的可行性与安全性。方法将53例CHF患者在接受基础治疗基础上随机分为小剂量组（雷米普利2．5～5mg／d），大剂量组（雷米普利10mg／d），治疗10周，观察治疗前后两组患者BNP浓度变化及各组间差异。结果CHF患者血浆中BNP浓度随着纽约心脏病协会心功能分级（NYHA）分级增加而升高，大剂量组比小剂量组能更明显降低血浆中BNP浓度。大剂量组患者采用小剂量逐渐递增剂量方式给药．耐受性良好。结论CHF时心力衰竭严重程度与血浆BNP浓度密切相关，血浆BNP浓度是评估CHF诊断、治疗和预后的良好的指标。在CHF患者中采用小剂量逐渐递增剂量的方式给予雷米普利安全可行．患者耐量性良好。
Objective We studied the relationship of plasma brain natriuretil peptide （BNP） level and severity of heart failure and investigated the influence of various dosage of ramipril onplasma BNP level, to discuss the feasibility and security of high dose of ramipril in chronic heart failure （CHF） patients. Methods Fifty- three patients with stable CHF who were receiving basic therapy for heart failure were randomly assigned to the low -dosegroup（ ramipril 2.5 -5 mg/d）and the high -dose group（ ramipril 10 mg/d）. All indices plasma BNP levels were measured before and after 10 weeks treatment,then compared the diferences between the two groups. Twenty healthy subjects were selected as control group. They were also examined with the plasma levels of BNP. Results The plasma BNP level was correlated closely with NYHA classes of heart failure in patients with CHF. The plasma BNP levels in the high -dose group were decreased more than those in the low - dose group. Patients in the high - dose group received ramipril at low dose initially and gradually increasing to the high dose, which tolerated well. Conclusion Plasma BNP levels in patients with CHF is correlated closely with the severity of CHF and plasma BNP level is a good examination of diagnosis, therapy and evaluating prognosis of CHF. Giving ramipril to patients in CHF at low dose initially and gradually increasing to the high dose was secure, and patients tolerated it well.
出处
《中原医刊》
2007年第23期9-10,共2页
Central Plains Medical Journal
关键词
慢性心力衰竭
血管紧张素转换酶抑制剂
雷米普利
脑钠肽
Chronic heart failure
Angiotensin convening enzyme inhibitor
Ramipril
Brain natriureic peptide
